Nirsevimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season
Agency for Care Effectiveness (ACE)
Record ID 32018016074
English
Details
Project Status:
Completed
Year Published:
2026
URL for published report:
https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nirsevimab-for-prevention-of-respiratory-syncytial-virus-associated-lower-respiratory-tract-disease-in-infants-during-their-first-rsv-season/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Singapore
MeSH Terms
- Respiratory Syncytial Virus Infections
- Infant
- Infant, Newborn
- Respiratory Tract Diseases
- Antibodies, Monoclonal, Humanized
- Primary Prevention
- Antiviral Agents
Contact
Organisation Name:
Agency for Care Effectiveness (ACE)
Contact Address:
Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name:
ACE_HTA@moh.gov.sg
Contact Email:
ACE_HTA@moh.gov.sg
Copyright:
Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.